Submitted by sandy craine on Fri, 17/01/2014 - 1:33pm
17th January 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.
17th January 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.
Submitted by sandy craine on Thu, 09/01/2014 - 12:57pm
December 31, 2013 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Dave Levitan
A small, hypolobated megakaryocyte in a bone marrow aspirate, typical ...
December 31, 2013 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Dave Levitan
A small, hypolobated megakaryocyte in a bone marrow aspirate, typical ...
Submitted by sandy craine on Thu, 02/01/2014 - 6:04pm
Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.
Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.
Submitted by sandy craine on Mon, 09/12/2013 - 1:46pm
Results of study: Personalized Cellular Therapy CTL019
NEW ORLEANS — Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
Results of study: Personalized Cellular Therapy CTL019
NEW ORLEANS — Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
Submitted by sandy craine on Tue, 03/12/2013 - 11:08pm
254 Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months.
254 Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months.
Submitted by sandy craine on Fri, 22/11/2013 - 3:02pm
22/11/2013
European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a number of recommendations to help minimise the risk of blood clots obstructing arteries or veins in patients taking the leukaemia medicine Iclusig.
22/11/2013
European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a number of recommendations to help minimise the risk of blood clots obstructing arteries or veins in patients taking the leukaemia medicine Iclusig.
Submitted by sandy craine on Tue, 19/11/2013 - 6:32pm
David M. Ross1,*, Susan Branford2, John F. Seymour3, Anthony P. Schwarer4, Christopher Arthur5, David T. Yeung6, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader7, Robin J. Filshie8, Anthony K. Mills9, Junia V. Melo10, Deborah L. White1, Andrew P. Grigg11, and Timothy P. Hughes1
David M. Ross1,*, Susan Branford2, John F. Seymour3, Anthony P. Schwarer4, Christopher Arthur5, David T. Yeung6, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader7, Robin J. Filshie8, Anthony K. Mills9, Junia V. Melo10, Deborah L. White1, Andrew P. Grigg11, and Timothy P. Hughes1
Submitted by sandy craine on Tue, 12/11/2013 - 9:16am
08/11/2013
PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig
Modification of product information under way to include strengthened warnings
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), at its 4-7 November meeting, reviewed new information on the cancer medicine Iclusig (ponatinib) that suggests that side effects such as vascular occlusive events (blood clots obstructing the arteries or veins) occur at a higher rate than initially observed at the time of granting the European Union (EU) marketing authorisation in July 2013.
08/11/2013
PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig
Modification of product information under way to include strengthened warnings
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), at its 4-7 November meeting, reviewed new information on the cancer medicine Iclusig (ponatinib) that suggests that side effects such as vascular occlusive events (blood clots obstructing the arteries or veins) occur at a higher rate than initially observed at the time of granting the European Union (EU) marketing authorisation in July 2013.
Submitted by sandy craine on Mon, 04/11/2013 - 11:09am
A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by researchers at Massachusetts General Hospital, the Harvard Stem Cell Institute and the Harvard Department of Stem Cell and Regenerative Biology.
A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by researchers at Massachusetts General Hospital, the Harvard Stem Cell Institute and the Harvard Department of Stem Cell and Regenerative Biology.
Submitted by sandy craine on Fri, 01/11/2013 - 10:16am
Silas Inman
Published Online: Thursday, October 31, 2013
Marketing and commercial distribution of ponatinib (Iclusig) has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of severe arterial thrombosis and stenosis.
Silas Inman
Published Online: Thursday, October 31, 2013
Marketing and commercial distribution of ponatinib (Iclusig) has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of severe arterial thrombosis and stenosis.
Pages
